Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements.

被引：3

作者：

Goyal, Lipika ^{[1
]}

Meric-Bernstam, Funda ^{[2
]}

Hollebecque, Antoine ^{[3
]}

Morizane, Chigusa ^{[4
]}

Valle, Juan W. ^{[5
]}

Karasic, Thomas B. ^{[6
]}

Abrams, Thomas A. ^{[7
]}

Kelley, Robin Kate ^{[8
]}

Cassier, Philippe ^{[9
]}

Furuse, Junji ^{[10
]}

Klumpen, Heinz-Josef ^{[11
]}

Chang, Heung-Moon ^{[12
]}

Chen, Li-Tzong ^{[13
]}

Komatsu, Yoshito ^{[14
]}

Masuda, Kunihiro ^{[15
]}

Ahn, Daniel ^{[16
]}

He, Yaohua ^{[17
]}

Soni, Nital ^{[18
]}

Benhadji, Karim A. ^{[17
]}

Bridgewater, John A. ^{[19
]}

机构：

[1] Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[3] Inst Gustave Roussy, Villejuif, France

[4] Natl Canc Ctr, Tokyo, Japan

[5] Univ Manchester, Manchester, Lancs, England

[6] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA

[7] Dana Farber Canc Inst, Boston, MA 02115 USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Ctr Leon Berard, Lyon, France

[10] Kyorin Univ, Tokyo, Japan

[11] Univ Amsterdam, Med Ctr, Amsterdam, Netherlands

[12] Asan Med Ctr, Seoul, South Korea

[13] Natl Inst Canc Res, Tainan, Taiwan

[14] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan

[15] Tohoku Univ, Sendai, Miyagi, Japan

[16] Mayo Clin, Phoenix, AZ USA

[17] Taiho Oncol Inc, Princeton, NJ USA

[18] Taiho Oncol, Princeton, NJ USA

[19] UCL, Canc Inst, London, England

来源：

CANCER RESEARCH | 2021年 / 81卷 / 13期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT010

引用

页数：2

共 50 条

[1] Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements
Moehler, M.
Goyal, L.
Meric-Bernstam, F.
Hollebecque, A.
Morizane, C.
Valle, J. W.
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P.
Furuse, J.
Klumpen, H. -J
Chang, H. -M
Chen, L. -T
Komatsu, Y.
Masuda, K.
Ahn, D.
He, Y.
Soni, N.
Benhadji, K. A.
Bridgewater, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 222 - 222
[2] Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Morizane, Chigusa
Valle, Juan W.
Karasic, Thomas Benjamin
Abrams, Thomas Adam
Kelley, Robin Kate
Cassier, Philippe Alexandre
Furuse, Junji
Klumpen, Heinz-Josef
Chang, Heung-Moon
Chen, Li-Tzong
Komatsu, Yoshito
Masuda, Kunihiro
Ahn, Daniel H.
Li, Kate
Benhadji, Karim A.
Wacheck, Volker
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[3] FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with FGFR2 fusions/rearrangements.
Valle, Juan W.
Hollebecque, Antoine
Furuse, Junji
Goyal, Lipika
Meric-Bernstam, Funda
Epstein, Robert S.
Salimi, Tehseen
Wacheck, Volker
Liu, Mei
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Foenix-CCA2 quality of life data for Futibatinib-treated intrahepatic cholangiocarcinoma (ICCA) patients with FGFR2 fusions/rearrangements
Moehler, M.
Valle, J. W.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Epstein, R.
Salimi, T.
Wacheck, V
Liu, M.
Benhadji, K. A.
Bridgewater, J. A.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 223 - 224
[5] Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/other rearrangements: Subgroup analyses of a phase II study (FOENIX-CCA2)
Bridgewater, J.
Meric-Bernstam, F.
Hollebecque, A.
Valle, J. W.
Morizane, C.
Karasic, T.
Abrams, T.
Furuse, J.
Kelley, R. K.
Cassier, P.
Klumpen, H-J.
Uboha, N.
Mahipal, A.
Mitchell, E.
Ahn, E. R.
Chang, H-M.
Masuda, K.
He, Y.
Benhadji, K.
Goyal, L.
ANNALS OF ONCOLOGY, 2020, 31 : S261 - S262
[6] Efficacy, safety, and quality of life (QoL) with futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements: FOENIX-CCA2
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Hollebecque, A.
Valle, J. W.
Morizane, C.
Karasic, T. B.
Abrams, T. A.
Kelley, R. K.
Cassier, P. A.
Klumpen, H-J.
Uboha, N.
Mahipal, A.
Mitchell, E.
Ahn, E.
Chang, H-M.
Masuda, K.
He, Y.
Benhadji, K. A.
Bridgewater, J. A.
ANNALS OF ONCOLOGY, 2020, 31 : S1288 - S1289
[7] FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.
Goyal, Lipika
Meric-Bernstam, Funda
Hollebecque, Antoine
Valle, Juan W.
Morizane, Chigusa
Karasic, Thomas Benjamin
Furuse, Junji
He, Yaohua
Soni, Nital
Benhadji, Karim A.
Bridgewater, John A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] PATIENT-REPORTED OUTCOMES IN FUTIBATINIB-TREATED INTRAHEPATIC CHOLANGIOCARCINOMA PATIENTS WITH FGFR2 FUSIONS/REARRANGEMENTS: RESULTS FROM THE FOENIX-CCA2 STUDY
Bridgewater, J. A.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Epstein, R. S.
Morlock, R.
Salimi, T.
Wacheck, V
Liu, M.
Benhadji, K.
Valle, J. W.
VALUE IN HEALTH, 2022, 25 (01) : S218 - S219
[9] Quality of life (QoL) outcomes with futibatinib treatment in FOENIX-CCA2-A phase II study in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions/rearrangements
Valle, J. W.
Hollebecque, A.
Furuse, J.
Goyal, L.
Meric-Bernstam, F.
Morlock, R.
He, Y.
Benhadji, K.
Bridgewater, J.
ANNALS OF ONCOLOGY, 2020, 31 : S263 - S264
[10] FOENIX-CCA4: A phase 2 study of futibatinib 20 mg and 16 mg in patients with advanced cholangiocarcinoma (CCA) and fibroblast growth factor receptor 2 (FGFR2) fusions/rearrangements.
Mizuno, Takashi
Brandi, Giovanni
Li, Jin
Chen, Ming-Huang
Kang, Jung Hun
Abdalla, Kathia Cristina
Wysocki, Piotr Jan
Couto, Nuno
Anderson, Bailey
Elsayed, Hamdy
Mantry, Parvez
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS572 - TPS572

← 1 2 3 4 5 →